Ion exchange resin treated to control swelling
The present invention provides a method and composition are provided that includes an ion exchange resin treated with from between about 0.01 to about 10 percent by weight of one or more sugar alcohols in contact with one or more ionic pharmaceutically active drug.
1. A method of preparing an ion exchange resin drug complex comprising the steps of:
contacting one or more ion exchange resin particles with one or more pharmaceutically active drugs,
adding about 0.01% to about 10% by weight of one or more sugar alcohols to the one or more ion exchange resin particles and one or more pharmaceutically active drugs, wherein the about 0.01% to about 10% by weight of one or more sugar alcohols is based on the combined weight of the one or more sugar alcohols, one or more pharmaceutically active drugs and the one or more ion exchange resin particles, and wherein the one or more sugar alcohols are distributed throughout the ion exchange resin particles, and
coating the ion exchange resin particles with a water-permeable diffusion barrier and wherein the weight of sugar alcohol in the coated particles is about 0.01% to about 10% of the combined weight of the one or more sugar alcohols, one or more pharmaceutically active drugs and the one or more ion exchange resin particles.
2. The method of claim 1 , wherein the one or more sugar alcohols is selected from the group consisting of mannitol, sorbitol, xylitol, maltitol, lactitol, 1,3-dihydroxypropane, inositol glucose, sucrose or combinations and mixtures thereof.
3. The method of claim 1 , wherein the ion exchange resin comprises polymers of dipropylene glycol diallyl ether, polyglycol diallyl ether, triethylene glycol divinyl ether, hydroquinone diallyl ether, tetraallyloxyethanoyl, vinyl ether, vinyl acetate, vinyl butylbenzoate, crontonic acid, polyfunctional alcohol, tetraethylene glycol diacrylate, triallylamine, trimethylolpropane diallyl ether, methylenebisacrylamide, divinylbenzene, phthalic, sulphonphthalic acid, ethylene glycol, polymethyl siloxane α,γ-hydroxypropyl or combinations thereof.
4. The method of claim 1 , wherein the active drug is selected from the group consisting of narcotic analgesics, sympathomimetics, antitussives, analgesics antiemetics, anticholinergics, muscle relaxants, bronchodilators, antibiotics, antidepressants, antiasthmatics, antineoplastics, antiepileptics, cardiovascular agents, mixtures and combinations thereof.
5. The method of claim 1 , wherein the active drug is selected from the group consisting of codeine, dihydrocodeine, hydromorphone, morphine, pentazocine, propoxyphene, norephedrine, pseudoephedrine, dextromethorphan, aspirin, tramadol, metoclopramide, atropine, ipratropium bromide, scopolamine, cyclobenzaprine, papaverine, salbutamol, terbutaline and theophylline, amoxicillin, ampicillin, azlocillin, bacampicillin, cefamandole, cefonicid, cefotaxime, cefotetan, cefoxitin, ceftriaxone, mezlocillin, piperacillin, bupropion, nomifensine, nortriptyline, cromolyn, tamoxifen, valproic acid and phenvtoin, propranolol mixtures and combinations thereof.
6. The method of claim 1 , wherein the one or more sugar alcohols are 0.1% to 5% by weight.
7. The method of claim 1 , wherein the one or more sugar alcohols are sorbitol.
8. The method of claim 1 , wherein the one or more sugar alcohols is sorbitol which is 0.1% to 5% by weight.
9. The method of claim 1 , further comprising filtering the ion exchange resin drug complex.
10. The method of claim 9 , wherein the ion exchange resin drug complex is not washed after the filtration.
11. The method of claim 1 , wherein the one or more sugar alcohols are added during the contacting of the one or more pharmaceutically active drugs with the one or more ion exchange resin particles.
12. The method of claim 1 , wherein the one or more sugar alcohols are added after the contacting of the one or more pharmaceutically active drugs with the one or more ion exchange resin particles.